Cargando…

EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer

Recent findings suggested a benefit of anti-EGFR therapy for basal-like muscle-invasive bladder cancer (MIBC). However, the impact on bladder cancer with substantial squamous differentiation (Sq-BLCA) and especially pure squamous cell carcinoma (SCC) remains unknown. Therefore, we comprehensively ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Michael, Maurer, Angela, Wirtz, Julia, Bleilevens, Andreas, Waldmann, Tanja, Wenz, Maximilian, Eyll, Marie, Geelvink, Mirja, Gereitzig, Melanie, Rüchel, Nadine, Denecke, Bernd, Eltze, Elke, Herrmann, Edwin, Toma, Marieta, Horst, David, Grimm, Tobias, Denzinger, Stefan, Ecke, Thorsten, Vögeli, Thomas Alexander, Knuechel, Ruth, Maurer, Jochen, Gaisa, Nadine T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605436/
https://www.ncbi.nlm.nih.gov/pubmed/32978523
http://dx.doi.org/10.1038/s41388-020-01465-y
_version_ 1783604302614364160
author Rose, Michael
Maurer, Angela
Wirtz, Julia
Bleilevens, Andreas
Waldmann, Tanja
Wenz, Maximilian
Eyll, Marie
Geelvink, Mirja
Gereitzig, Melanie
Rüchel, Nadine
Denecke, Bernd
Eltze, Elke
Herrmann, Edwin
Toma, Marieta
Horst, David
Grimm, Tobias
Denzinger, Stefan
Ecke, Thorsten
Vögeli, Thomas Alexander
Knuechel, Ruth
Maurer, Jochen
Gaisa, Nadine T.
author_facet Rose, Michael
Maurer, Angela
Wirtz, Julia
Bleilevens, Andreas
Waldmann, Tanja
Wenz, Maximilian
Eyll, Marie
Geelvink, Mirja
Gereitzig, Melanie
Rüchel, Nadine
Denecke, Bernd
Eltze, Elke
Herrmann, Edwin
Toma, Marieta
Horst, David
Grimm, Tobias
Denzinger, Stefan
Ecke, Thorsten
Vögeli, Thomas Alexander
Knuechel, Ruth
Maurer, Jochen
Gaisa, Nadine T.
author_sort Rose, Michael
collection PubMed
description Recent findings suggested a benefit of anti-EGFR therapy for basal-like muscle-invasive bladder cancer (MIBC). However, the impact on bladder cancer with substantial squamous differentiation (Sq-BLCA) and especially pure squamous cell carcinoma (SCC) remains unknown. Therefore, we comprehensively characterized pure and mixed Sq-BLCA (n = 125) on genetic and protein expression level, and performed functional pathway and drug-response analyses with cell line models and isolated primary SCC (p-SCC) cells of the human urinary bladder. We identified abundant EGFR expression in 95% of Sq-BLCA without evidence for activating EGFR mutations. Both SCaBER and p-SCC cells were sensitive to EGFR tyrosine kinase inhibitors (TKIs: erlotinib and gefitinib). Combined treatment with anti-EGFR TKIs and varying chemotherapeutics led to a concentration-dependent synergism in SCC cells according to the Chou-Talalay method. In addition, the siRNA knockdown of EGFR impaired SCaBER viability suggesting a putative “Achilles heel” of Sq-BLCA. The observed effects seem Sq-BLCA-specific since non-basal urothelial cancer cells were characterized by poor TKI sensitivity associated with a short-term feedback response potentially attenuating anti-tumor activity. Hence, our findings give further insights into a crucial, Sq-BLCA-specific role of the ERBB signaling pathway proposing improved effectiveness of anti-EGFR based regimens in combination with chemotherapeutics in squamous bladder cancers with wild-type EGFR-overexpression.
format Online
Article
Text
id pubmed-7605436
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-76054362020-11-12 EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer Rose, Michael Maurer, Angela Wirtz, Julia Bleilevens, Andreas Waldmann, Tanja Wenz, Maximilian Eyll, Marie Geelvink, Mirja Gereitzig, Melanie Rüchel, Nadine Denecke, Bernd Eltze, Elke Herrmann, Edwin Toma, Marieta Horst, David Grimm, Tobias Denzinger, Stefan Ecke, Thorsten Vögeli, Thomas Alexander Knuechel, Ruth Maurer, Jochen Gaisa, Nadine T. Oncogene Article Recent findings suggested a benefit of anti-EGFR therapy for basal-like muscle-invasive bladder cancer (MIBC). However, the impact on bladder cancer with substantial squamous differentiation (Sq-BLCA) and especially pure squamous cell carcinoma (SCC) remains unknown. Therefore, we comprehensively characterized pure and mixed Sq-BLCA (n = 125) on genetic and protein expression level, and performed functional pathway and drug-response analyses with cell line models and isolated primary SCC (p-SCC) cells of the human urinary bladder. We identified abundant EGFR expression in 95% of Sq-BLCA without evidence for activating EGFR mutations. Both SCaBER and p-SCC cells were sensitive to EGFR tyrosine kinase inhibitors (TKIs: erlotinib and gefitinib). Combined treatment with anti-EGFR TKIs and varying chemotherapeutics led to a concentration-dependent synergism in SCC cells according to the Chou-Talalay method. In addition, the siRNA knockdown of EGFR impaired SCaBER viability suggesting a putative “Achilles heel” of Sq-BLCA. The observed effects seem Sq-BLCA-specific since non-basal urothelial cancer cells were characterized by poor TKI sensitivity associated with a short-term feedback response potentially attenuating anti-tumor activity. Hence, our findings give further insights into a crucial, Sq-BLCA-specific role of the ERBB signaling pathway proposing improved effectiveness of anti-EGFR based regimens in combination with chemotherapeutics in squamous bladder cancers with wild-type EGFR-overexpression. Nature Publishing Group UK 2020-09-25 2020 /pmc/articles/PMC7605436/ /pubmed/32978523 http://dx.doi.org/10.1038/s41388-020-01465-y Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Rose, Michael
Maurer, Angela
Wirtz, Julia
Bleilevens, Andreas
Waldmann, Tanja
Wenz, Maximilian
Eyll, Marie
Geelvink, Mirja
Gereitzig, Melanie
Rüchel, Nadine
Denecke, Bernd
Eltze, Elke
Herrmann, Edwin
Toma, Marieta
Horst, David
Grimm, Tobias
Denzinger, Stefan
Ecke, Thorsten
Vögeli, Thomas Alexander
Knuechel, Ruth
Maurer, Jochen
Gaisa, Nadine T.
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
title EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
title_full EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
title_fullStr EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
title_full_unstemmed EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
title_short EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer
title_sort egfr activity addiction facilitates anti-erbb based combination treatment of squamous bladder cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605436/
https://www.ncbi.nlm.nih.gov/pubmed/32978523
http://dx.doi.org/10.1038/s41388-020-01465-y
work_keys_str_mv AT rosemichael egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT maurerangela egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT wirtzjulia egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT bleilevensandreas egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT waldmanntanja egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT wenzmaximilian egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT eyllmarie egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT geelvinkmirja egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT gereitzigmelanie egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT ruchelnadine egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT deneckebernd egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT eltzeelke egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT herrmannedwin egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT tomamarieta egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT horstdavid egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT grimmtobias egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT denzingerstefan egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT eckethorsten egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT vogelithomasalexander egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT knuechelruth egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT maurerjochen egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer
AT gaisanadinet egfractivityaddictionfacilitatesantierbbbasedcombinationtreatmentofsquamousbladdercancer